A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis | Zendy

Robert F. Betts | Zendy; Márcio Nucci | Zendy; Deepak Talwar | Zendy; Marcelo Gareca | Zendy; Flávio QueirozTelles | Zendy; Roger Bedimo | Zendy; Raoul Herbrecht | Zendy; Guillermo M. RuizPalacios | Zendy; JoAnne H. Young | Zendy; John W. Baddley | Zendy; Kim M. Strohmaier | Zendy; Kimberly A. Tucker | Zendy; Arlene F. Taylor | Zendy; Nicholas A. Kartsonis | Zendy

Open Access

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

Author(s) -

Robert F. Betts,

Márcio Nucci,

Deepak Talwar,

Marcelo Gareca,

Flávio QueirozTelles,

Roger Bedimo,

Raoul Herbrecht,

Guillermo M. RuizPalacios,

JoAnne H. Young,

John W. Baddley,

Kim M. Strohmaier,

Kimberly A. Tucker,

Arlene F. Taylor,

Nicholas A. Kartsonis

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/598933

Subject(s) - caspofungin , regimen , medicine , neutropenia , adverse effect , dosing , population , surgery , chemotherapy , amphotericin b , antifungal , dermatology , environmental health

The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research